Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF–TrkB Signaling
- 528 Downloads
Depression is a debilitating psychiatric disorder with a huge socioeconomic burden, and its treatment relies on antidepressants including selective serotonin reuptake inhibitors (SSRIs). Recently, the melatonergic system that is closely associated with the serotonergic system has been implicated in the pathophysiology and treatment of depression. However, it remains unknown whether combined treatment with SSRI and melatonin has synergistic antidepressant effects. In this study, we applied a sub-chronic restraint stress paradigm, and evaluated the potential antidepressant effects of combined fluoxetine and melatonin in adult male mice. Sub-chronic restraint stress (6 h/day for 10 days) induced depression-like behavior as shown by deteriorated fur state, increased latency to groom in the splash test, and increased immobility time in the forced-swim test. Repeated administration of either fluoxetine or melatonin at 10 mg/kg during stress exposure failed to prevent depression-like phenotypes. However, combined treatment with fluoxetine and melatonin at the selected dose attenuated stress-induced behavioral abnormalities. Moreover, we found that the antidepressant effects of combined treatment were associated with the normalization of brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB) signaling in the hippocampus, but not in the prefrontal cortex. Our findings suggest that combined fluoxetine and melatonin treatment exerts synergistic antidepressant effects possibly by restoring hippocampal BDNF–TrkB signaling.
KeywordsMelatonin Fluoxetine Depression BDNF TrkB
We thank the Core Facilities of Zhejiang University Institute of Neuroscience for technical assistance. This work was supported by the National Natural Science Foundation of China (81471369) and Innovative Experiments on Physiology of Zhejiang University School of Medicine. The authors have no conflicting financial interests.
- 1.Seo JS, Zhong P, Liu A, Yan Z, Greengard P. Elevation of p11 in lateral habenula mediates depression-like behavior. Mol Psychiatry 2017. doi: 10.1016/j.pbb.2017.02.004.
- 36.Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002, 301: 333–345.CrossRefPubMedGoogle Scholar
- 39.Di Liberto V, Frinchi M, Verdi V, Vitale A, Plescia F, Cannizzaro C, et al. Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 levels in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) 2017, 234: 559–573.CrossRefGoogle Scholar
- 43.Souza LC, Filho CB, Fabbro LD, de Gomes MG, Goes AT, Jesse CR. Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice: the protective effect of fluoxetine, antitumour necrosis factor-alpha and thalidomide therapies. Behav Pharmacol 2013, 24: 79–86.CrossRefPubMedGoogle Scholar